Medrysone
Based on 1 publication(s) in Google Scholar
Medrysone (HMS) is a glucocorticoid receptor modulator and a STAT6 pathway enhancer. Medrysone enhances cytokine-induced STAT6 phosphorylation, which is required for M2-type macrophage polarization, and promotes VEGF and CCL2 secretion, vascular endothelial cell migration, and corneal injury repair. Medrysone can be used in research on corneal injury and elevated intraocular pressure.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.79%
- CAS No.: 2668-66-8
- Formule: C22H32O3
- Masse moléculaire:344.49
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Medrysone
MoreVoir tous les produits spécifiques à Isoform VEGFR
More
Activité biologique
Description
|
STAT6 |
CCL2 |
GR |
VEGF |
In Vitro
Medrysone (5 µM; 24 h), when combined with IL-4, upregulates the mRNA expression levels of M2 marker genes (Mrc1, IL10, Fizz1, Arg1, CD11b) in RAW264.7 cells, and these levels are higher than those observed with either agent alone[1].
Medrysone (1-25 μM; 48 h) is a class I glucocorticoid that upregulates MBP protein in Oli-neuM cells[3].
Medrysone (10 μM; 48 h) increases MBP, PLP/DM20, CNP, and MOG myelin gene expression in Oli-neuM cells[3].
Medrysone (10 μM) upregulates RxRγ but not Gli1, and induces only weak NR3C1 activation in Oli-neuM cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW264.7 murine macrophages
-
Concentration:5 µM (Medrysone); 10 ng/mL (IL-4)
-
Incubation Time:24 h
-
Result:mRNA expression of M2 marker genes Mrc1, IL10, Fizz1, Arg1, and CD11b was up-regulated in RAW264.7 cells.
-
Cell Line:RAW264.7 murine macrophages
-
Concentration:5 μM
-
Incubation Time:24 h
-
Result:Increased p-STAT6 levels relative to control when used alone.
Further enhanced p-STAT6 levels to a relative value of 1.44 (short exposure) when combined with IL-4, which is higher than the 0.75 relative value observed with IL-4 alone.
-
Cell Line:C166 murine vascular endothelial cells, RAW264.7 murine macrophage cells
-
Concentration:5 μM
-
Incubation Time:24 h (treatment of RAW264.7 cells)
-
Result:Increased C166 cell migration to a fold change of approximately 0.9 when using conditioned medium from Medrysone-treated RAW264.7 cells.
Increased C166 cell migration to a fold change of approximately 2.3 when using conditioned medium from RAW264.7 cells treated with both Medrysone and IL-4, which is higher than the fold change of approximately 1.8 observed with conditioned medium from IL-4-treated cells.\
Enhanced C166 cell wound closure when using conditioned medium from Medrysone-treated RAW264.7 cells.
Induced the strongest wound closure when using conditioned medium from RAW264.7 cells treated with both Medrysone and IL-4.
-
Cell Line:human mesenchymal stem cells (hMSCs)
-
Concentration:1, 10, and 100 nM
-
Incubation Time:up to 21 days
-
Result:Supported cell proliferation comparable to cells grown in complete osteogenic media (OG+) over 21 days at 100 nM, with cells remaining attached to TCPS throughout the study.
Increased ALP activity slightly relative to OG+ at 14 days, and by ~25% relative to OG+ at 21 days at 100 nM.
Elevated relative CBFA1 expression slightly above day 0 levels at 14, 18, and 21 days, but lower than OG+ levels at 18 days at 100 nM.
Increased relative osteocalcin expression over time, with levels slightly elevated above day 0 but lower than OG+ at 21 days at 100 nM.
Resulted in significantly less mineralized matrix deposition relative to OG+, with only minimal Alizarin Red staining observed after 21 days at 100 nM.
-
Cell Line:human mesenchymal stem cells (hMSCs)
-
Concentration:100 nM
-
Incubation Time:14, 18, and 21 days
-
Result:CBFA1 levels were slightly elevated from starting hMSC levels, with little overall variation among inducers; Fig. 6A marked group differences at day 18.
Osteocalcin expression was measured at 14, 18, and 21 days (Fig. 6B); no 2.5-fold increase over OG+ at 21 days reported for TD was observed.
-
Cell Line:human mesenchymal stem cells (hMSCs)
-
Concentration:100 nM
-
Incubation Time:21 days
-
Result:100 nM cultures had less Alizarin Red staining than OG+ controls; only FC-treated hMSCs deposited matrix comparable to OG+; OG− cultures showed no staining.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:male, 6-8 weeks old[1]
-
Dosage:5 μM
-
Administration:every 6 h for 48 h
-
Result:In the rat corneal mechanical injury model (n = 6 per group), corneal damage repair was promoted as assessed by fluorescein sodium staining after 48 h.
Increased corneal tissue mRNA expression of the M2 markers Mrc1, Fizz1, Arg1, and CD11b.
- Western Blot
- Scratch/Wound-Healing Migration Assay
- Cell migration
- Neural Crest/Neuronal Cell Migration Explant Assay
- Research Protocol for Inflammation-related Diseases
- Kinase activity and phosphorylation assays
- Phagocytosis Functional Assay
- Zigmond Chamber Chemotaxis Assay
- Research Protocol for Endocrine Diseases
- Under-Agarose Cell Migration Assay
- Transwell/Boyden Chamber Migration Assay
- Primary monocyte-to-macrophage differentiation
- 3D Collagen/Hydrogel Matrix Migration Assay
- Protocol for Kinase activity and phosphorylation assays
- Cell-Exclusion Zone Migration Assay
- Dunn/Insall Chamber Chemotaxis Assay
- Endothelial Cell Migration/Angiogenic Sprouting Assay
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2668-66-8
-
Appearance Solid
-
Masse moléculaire 344.49
-
Formule C22H32O3
-
Color White to off-white
-
SMILES
CC([C@H]1CC[C@@]2([H])[C@]3([H])C[C@H](C)C4=CC(CC[C@]4(C)[C@@]3([H])[C@@H](O)C[C@]12C)=O)=O
-
Synonyms
HMS; 6α-Methyl-11β-hydroxyprogesterone
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Coronavirus envelope protein activates TMED10-mediated unconventional secretion of inflammatory factors. [Abstract]2024 Oct 8;15(1):8708. PMID: 39379362
Solvant et solubilité
In Vitro:
DMSO : 50 mg/mL (145.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : ≥ 25 mg/mL (72.57 mM)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (7.26 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (292 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Zhu Y, et al. Medrysone promotes corneal injury repair by promoting M2-like polarization of macrophages. BMC Ophthalmol. 2023 Dec 11;23(1):503. [Content Brief]
[2]. Brey DM, et al. High-throughput screening of a small molecule library for promoters and inhibitors of mesenchymal stem cell osteogenic differentiation. Biotechnology and bioengineering. 2011 Jan;108(1):163-74. [Content Brief]
[3]. Porcu G, et al. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation. PLoS One. 2015 Dec 10;10(12):e0144550. [Content Brief]
[4]. Southren AL, et al. Nuclear translocation of the cytoplasmic glucocorticoid receptor in the iris-ciliary body and adjacent corneoscleral tissue of the rabbit following topical administration of various glucocorticoids. A rapid screening method for glucocorticoid activity. Invest Ophthalmol Vis Sci. 1983 Feb;24(2):147-52. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.9028 mL | 14.5142 mL | 29.0284 mL | 72.5710 mL |
| 5 mM | 0.5806 mL | 2.9028 mL | 5.8057 mL | 14.5142 mL | |
| 10 mM | 0.2903 mL | 1.4514 mL | 2.9028 mL | 7.2571 mL | |
| 15 mM | 0.1935 mL | 0.9676 mL | 1.9352 mL | 4.8381 mL | |
| 20 mM | 0.1451 mL | 0.7257 mL | 1.4514 mL | 3.6286 mL | |
| 25 mM | 0.1161 mL | 0.5806 mL | 1.1611 mL | 2.9028 mL | |
| 30 mM | 0.0968 mL | 0.4838 mL | 0.9676 mL | 2.4190 mL | |
| 40 mM | 0.0726 mL | 0.3629 mL | 0.7257 mL | 1.8143 mL | |
| 50 mM | 0.0581 mL | 0.2903 mL | 0.5806 mL | 1.4514 mL | |
| 60 mM | 0.0484 mL | 0.2419 mL | 0.4838 mL | 1.2095 mL | |
| DMSO | 80 mM | 0.0363 mL | 0.1814 mL | 0.3629 mL | 0.9071 mL |
| 100 mM | 0.0290 mL | 0.1451 mL | 0.2903 mL | 0.7257 mL |
Medrysone Related Classifications
HY-B1076 Related Classifications
Powered by Bioz